Anna Edney
Verified
National health care reporter for Bloomberg News. Of course, tweets are my own, RTs are not endorsements.
Articles by Anna Edney
UK Drugmaker in Talks to Boost Estrogen Patch Supply in US Original
(Bloomberg) -- A London-based drugmaker is in discussions with the US government to supply American women with its estrogen patches as the nation struggles to keep up with surging demand.
US Parents Face Record Surge in Baby Food and Formula Costs Original
Baby food and formula prices surged by the most on record last month, exacerbating the financial burden facing families with young children. US prices for baby food and formula rose 5.1% in October, according to data out Tuesday. The costs of a variety of essentials, including other groceries, car insurance, day care, rent and electricity also increased in the month.
US Parents Face Record Surge in Baby Food and Formula Costs
Bureau of Labor Statistics (Bloomberg) -- Baby food and formula prices surged by the most on record last month, exacerbating the financial burden facing families with young children.
ByHeart Executives to Buy Perrigo’s Infant Formula Business
(Bloomberg) -- A company led by executives of ByHeart, the infant-formula maker whose product sickened dozens of babies with botulism last year, will buy Perrigo Co.’s infant-formula business for up to $175 million, Perrigo said Thursday.
Boston Scientific Falls on Sales Hit After Prior Cyberattack
Photographer: Lane Turner/The Boston Globe/Getty Images (Bloomberg) -- Boston Scientific Corp.’s shares dropped after it lowered its sales outlook and said it expects fourth-quarter sales to decline.
Boston Scientific Falls on Sales Hit After August Cyberattack
Consumer Tech 1 hour ago Amazon introduces a host of new smart home devices: Meet the updated Echo line Mashable - Miller Kern • 1h We're getting new Amazon devices just in time for the holidays. Amazon has made several new product announcements this year — including the exciting new Kindle lineup. The retail giant is back with another round of updates; this time in the smart home space.
Abbott Spins Off Embattled Business That Sells Baby Formula (3) Original
said it plans to spin off its nutrition unit after a series of missteps with its iconic brands including the infant formula Similac, narrowing its remaining business to focus on core healthcare products. The move will create a separate publicly traded company through a tax-free distribution to shareholders that’s expected to be completed by the end of 2027, Abbott said in a . The still-unnamed company will have annual sales of about $8.5 billion from its key brands, including Pedialyte and Ensure.
Abbott plans to spin off its embattled nutrition unit
Introducing 40 young leaders already putting their imprint on the businesses, institutions and communities shaping our future.
Abbott Spins Off Embattled Business That Sells Baby Formula
Photographer: Bing Guan/Bloomberg (Bloomberg) -- Abbott Laboratories said it plans to spin off its nutrition unit after a series of missteps with its iconic brands including the infant formula Similac, narrowing its remaining business to focus on...
Abbott to spin off baby formula business
Abbott Laboratories said it plans to spin off its nutrition unit into a separate publicly traded company after a series of missteps have weighed on the company's broader performance. (Oct 21): Abbott Laboratories said it plans to spin off its nutrition unit into a separate publicly traded company after a series of missteps have weighed on the company's broader performance.
Black mold, bugs found at Chinese plants making GLP-1 compounding agents
U.S. inspectors documented egregious conditions at two Chinese factories making key components for compounded GLP-1 drugs popular in America, including black mold on equipment and “gross contamination” on floors at one plant. The inspectors caught employees trying to hide paperwork and furtively pouring out product samples at that plant and evidence of bogus documentation at the other, according to reports obtained under a Freedom of Information Act request.
Black Mold, Bugs Found at Chinese Plants Making GLP-1 Compounding Agents
(Bloomberg) -- US inspectors documented egregious conditions at two Chinese factories making key components for compounded GLP-1 drugs popular in America, including black mold on equipment and “gross contamination” on floors at one plant.
愛犬・愛猫にもアンチエイジング薬、試さずにいられない飼い主の願い「永遠に一緒に」
エイミー・グリーンさんは、飼っている2匹の犬、ブルータスとオニキスにペプチドを投与している。自身が長寿目的でペプチド療法を受けており、2匹にも効果があると考えているからだ。一方、アンチエイジング目的でラパマイシンという錠剤を週1回服用しているダニエル・タウフィクさんは、飼い猫のラギーとラスカルにも少量をこっそり与えている。...
Abbott to Pay $385 Million to End Claims Over Infant Formula
Abbott Laboratories agreed to pay $385 million to settle U.S. allegations related to poor manufacturing practices at two facilities, including one involving an investigation of a contaminated facility that made powder infant formula.
Abbott to Pay $385 Million to End US Claims Over Infant Formula
Abbott Laboratories agreed to pay $385 million to settle U.S. allegations related to poor manufacturing practices at two facilities, including one involving an investigation of a contaminated facility that made powder infant formula.
Abbott to Pay $385 Million to End US Claims Over Infant Formula
Sept. 14, 2026, 6:44 PM UTC Abbott Laboratories agreed to pay $385 million to settle US allegations related to poor manufacturing practices at two facilities, including one involving an investigation of a contaminated facility that made powder infant formula.
Abbott to Pay $385 Million to End US Claims Over Infant Formula
Photographer: Matthew Hatcher/Bloomberg (Bloomberg) -- Abbott Laboratories agreed to pay $385 million to settle US allegations related to poor manufacturing practices at two facilities, including one involving an investigation of a contaminated...
Labcorp Unveils Long-Term Outlook Driven by Specialty Testing
Source: Labcorp (Bloomberg) -- Labcorp Holdings Inc. is providing an ambitious long-term plan for investors as the laboratory services company anticipates continued growth in personalized medicine.
Boston Scientific, Stryker Drop on Fallout From Cyber Attacks
and shares fell after the medical device companies said they are dealing with the repercussions of separate cyber attacks that curtailed their ability to get products to customers and dented sales, with damage that could last for months. Boston Scientific in a regulatory filing that it doesn’t expect to meet expectations for net sales or adjusted earnings per share for the third quarter or the full year because of the cyber incident it disclosed .
Boston Scientific, Stryker Drop on Fallout From Cyber Attacks
Bloomberg News (Bloomberg) -- Boston Scientific Corp. and Stryker Corp.
Reckitt Shares Rebound as Mead Johnson Wins Infant Formula Trial
shares rebounded after a US jury sided with the company in a bellwether trial among a group of cases alleging that formula for premature babies is linked to a deadly bowel disease. The unanimous verdict in favor of Reckitt’s Mead Johnson unit in the US District Court for the Northern District of Illinois means the company doesn’t face any outstanding jury verdicts in the overall litigation involving the disease, known as necrotizing enterocolitis or NEC, Mead Johnson said Monday.
Reckitt Shares Rebound as Mead Johnson Wins Infant Formula Trial
Bloomberg (Bloomberg) -- Reckitt Benckiser Group Plc shares rebounded after a US jury sided with the company in a bellwether trial among a group of cases alleging that formula for premature babies is linked to a deadly bowel disease.
Abbott targets wary parents with liquid whole milk formula
These 14 families wield influence across Chicago and Illinois through business, politics, philanthropy, sports and civic institutions.
Abbott Targets Wary Parents With Liquid Whole Milk Formula
will begin selling a new ready-to-feed version of its Similac infant formula Monday, marking the first time whole milk has been used in sterile liquid formula in the US. The move offers another option to nervous parents after powdered formula made with whole milk was linked to dozens of starting last year.
Abbott Targets Wary Parents With Liquid Whole Milk Formula
Photographer: Matthew Hatcher/Bloomberg (Bloomberg) -- Abbott Laboratories will begin selling a new ready-to-feed version of its Similac infant formula Monday, marking the first time whole milk has been used in sterile liquid formula in the US.
Abbott Will Pay $670 Million to End 2,000 Infant Formula Claims
Photographer: Bing Guan/Bloomberg (Bloomberg) -- Abbott Laboratories agreed to pay $670 million to settle some lawsuits alleging that it hid the risk that its infant formula for premature babies can cause a deadly bowel disease.
Pet Owners Want Cats and Dogs to Live Forever. Enter Anti-Aging Drugs and Peptides Original
Amy Greene uses peptide injections in hopes of living longer and figures her two dogs, Brutus and Onyx, could use the shots too.
Trump’s Latest Tariff Threat Could Lead to Generic Drug Shortages Original
Welcome back to Bloomberg’s Health Monitor, a weekly look at the boardroom decisions, scientific advances and policy fights shaping the future of medicine. Sign up now if you’re not already on the list.
研究顯示中國批准的抗癌新藥數量超過美國
Health Affairs 【彭博】-- 周一發表的一項研究顯示,過去幾年,中國藥品監管部門批准上市的抗癌新藥數量超過美國監管機構。該研究表明,對中國生物科技行業的投資正在提升其全球競爭力。 2020年至2025年間,中國國家藥品監督管理局共批准94款新型腫瘤藥上市,而美國食品藥品監督管理局同期批准87款。這項發表於《Health Affairs》期刊的研究顯示,2025年,中國批准的抗癌藥數量接近美國的三倍。該研究由賓夕法尼亞大學和倡導組織Friends of Cancer Research的研究人員完成。 數據顯示,在研究覆蓋時段內,2020年至2022年,美國食品藥品監督管理局批准的藥物數量均高於中國,但這一局面在2023年發生逆轉,此後至2025年中國一直領先美國。 不過,數據顯示,中國獲批的許多腫瘤藥是一些已在美國上市一段時間藥物的中國本土版本。在將同類首創藥物推向市場方面,美國仍占據主導地位。...
Кина одобрила повеќе нови лекови против рак одошто САД
Кинеските здравствени власти одобриле повеќе нови лекови за третман на канцер од нивните американски колеги во последните неколку години, според студија објавена во понеделник, која покажува дека инвестициите во кинеската биотехнолошка индустрија ја зголемуваат нејзината конкурентност на глобално ниво.
Cancer Drug Approvals in China Outpace Those in US, Study Finds Original
Photographer: Gilles Sabrie/Bloomberg (Bloomberg) -- Chinese health authorities approved more novel cancer drugs than their US counterparts in the last several years, according to a study published Monday that shows investments in China’s...
Abbott Boosts 2026 Profit Guidance as Sales Across Business Rise Original
raised its 2026 profit guidance after a stronger-than-expected second quarter driven by improved performance across most of its business lines. The company now expects adjusted earnings to fall between $5.45 to $5.60 a share this year, a 5-cent improvement at the midpoint, it said in a Thursday. Profit and sales in the second quarter both surpassed Wall Street estimates. Shares rose 2.7% in early trading in New York. Abbott’s device and diabetes businesses modestly beat Wall Street estimates.
Abbott Laboratories Surges on 2026 Profit Guidance Raise
Photographer: Bing Guan/Bloomberg (Bloomberg) -- Abbott Laboratories soared the most in 24 years after raising its 2026 profit guidance following a stronger-than-expected second quarter driven by improved performance across most of its business...
FDA Urges More Baby Formula Supply Chain Oversight After Recalls Original
Infant formula makers and distributors should increase their supply chain monitoring in the wake of babies hospitalized by contaminated products and several voluntary recalls that have rocked the US sector over the last year, federal food safety regulators said Monday. Recent recalls “reflect a pattern that warrants attention from both FDA and the infant formula industry,” said the open letter addressing the infant formula industry.
Dreyer’s Sanitation Inspection Flags Ice Cream Sandwiches, Drumsticks
(Bloomberg) -- A Dreyer’s Grand Ice Cream factory in California was flagged for repeated sanitation failures and bacterial contamination during an inspection earlier this year, including employees who touched trash cans then returned to working...
Almost $1B later, the US still can’t make a medical glove
A dark gray building full of steel tanks and giant reactors sits at the foot of the Blue Ridge Mountains in Southern Virginia, a hulking symbol of an abandoned effort to make more medical gloves in the U.S.
A Nearly $1 Billion US Medical Manufacturing Flop
Scott Maier, CEO of Blue Star NBR in Virginia.Photographer: Jesse Barber/Bloomberg July 9, 2026 at 11:05 AM UTC Welcome back to Bloomberg’s Health Monitor, a weekly look at the boardroom decisions, scientific advances and policy fights shaping the...
Almost US$1 bil later, the US still can't make a medical glove
"I'm out of money," said Scott Maier, Blue Star's chief executive officer. "I've got nothing left to mortgage." ARLINGTON (July 8): A dark gray building full of steel tanks and giant reactors sits at the foot of the Blue Ridge Mountains in Southern Virginia, a hulking symbol of an abandoned effort to make more medical gloves in the US.
Almost $1 billion later, the US still can't make a medical glove
(Bloomberg) -- A dark gray building full of steel tanks and giant reactors sits at the foot of the Blue Ridge Mountains in Southern Virginia, a hulking symbol of an abandoned effort to make more medical gloves in the US. With $123 million in financing from the federal government, the factory was to have been the first in the nation in more than 30 years to produce a key ingredient in the gloves used in exam rooms and hospitals across the country.
Almost $1 Billion Later, the US Still Can’t Make a Medical Glove
A dark gray building full of steel tanks and giant reactors sits at the foot of the Blue Ridge Mountains in Southern Virginia, a hulking symbol of an abandoned effort to make more medical gloves in the US. With $123 million in financing from the federal government, the factory was to have been the first in the nation in more than 30 years to produce a key ingredient in the gloves used in exam rooms and hospitals across the country.
Almost $1 Billion Later, the US Still Can’t Make a Medical Glove
A dark gray building full of steel tanks and giant reactors sits at the foot of the Blue Ridge Mountains in Southern Virginia, a hulking symbol of an abandoned effort to make more medical gloves in the US. With $123 million in financing from the federal government, the factory was to have been the first in the nation in more than 30 years to produce a key ingredient in the gloves used in exam rooms and hospitals across the country.
Heavy Metals in Tampons Aren’t Cause for Concern, Regulators Say Original
A new study from the US Food and Drug Administration confirmed the presence of heavy metals like arsenic and lead in several tampon brands, but the agency said they aren’t released at levels high enough to cause concern. The FDA’s study, published in the journal Toxicological Sciences, was a follow-up to that found more than a dozen metals in widely used tampons.
Needles Used to Detect Breast Cancer in Shortage From Recall (1) Original
The said that the US is experiencing a shortage of breast biopsy needles after recalled the products earlier this year, potentially causing delays in diagnosing the most common cancer in women. The shortage is expected to last through March 2027, the FDA said in a statement. It advised doctors to take measures to conserve their supply of needles. Hologic started a recall in January following reports of metal and plastic pieces dislodging from the needles and getting stuck in patients’ bodies.
Needles used to detect breast cancer in shortage from recall
; ; ; Continue reading More for You Continue reading More for You
Needles Used to Detect Breast Cancer in Shortage From Recall Original
(Bloomberg) -- The Food and Drug Administration said that the US is experiencing a shortage of breast biopsy needles after Hologic Inc. recalled the products earlier this year, potentially causing delays in diagnosing the most common cancer in women.
Infant Botulism Leads to Recall of Another Baby Formula Brand Original
Nara Organics recalled all of its whole milk infant formula after three babies were hospitalized with confirmed or suspected botulism, the second total recall of a baby formula brand after it was linked to the deadly illness. The US Centers for Disease Control and Prevention warned parents not to use Nara’s formula, which is sold on the company’s website and at , on Saturday after three babies confirmed to have consumed it contracted botulism.
Infant Botulism Leads to Recall of Another Baby Formula Brand
Nara Organics Infant Formula Source: Business Wire June 15, 2026 at 12:43 PM UTC Nara Organics recalled all of its whole milk infant formula after three babies were hospitalized with confirmed or suspected botulism, the second total recall of a...
Show More
loading
Actions
Get in touch with Anna
Contact Anna, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack